CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
MCV4 OBTAINS DRUG REGISTRATION CERTIFICATE IN ARGENTINA

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the Company's Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the "**MCV4**", trade name: Menhycia®) has received the drug registration certificate granted by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.

The Company's Menhycia® has been approved in China for use in children aged 3 months to 6 years (83 months). Vaccination of Menhycia® triggers immune response against Group ACYW135 Neisseria meningitidis and is used for the prevention of epidemic cerebrospinal meningitis associated with Group ACYW135 Neisseria meningitidis. Clinical trials conducted in China have demonstrated good safety and immunogenicity profiles, providing a superior solution for the prevention of meningococcal meningitis in children aged 6 years and below. The clinical summary report for the Menhycia® age-expansion clinical trial for subjects aged 7 to 59 years has been completed, and preparations for the supplemental application are currently underway.

The obtainment of the drug registration certificate for the Company's MCV4 in Argentina marks a significant achievement in the product's internationalization strategy and enhances the Company's global recognition. In terms of international business development, the Company will continue to focus on key overseas markets, with a core emphasis on Southeast Asia, the Middle East, and Latin America. We will leverage our products' competitive advantages in overseas markets and advance external collaborations and product supply through technology transfer, as well as the supply of intermediates and finished products.

The specific timeline and amount of sales of MCV4 in Argentina remain uncertain, and will depend on the market demand from the approved indicated population.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 25, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.